Success Stories: An Indian Graduate Assistant in Pharmaceutical Science with 39 Peer Reviews Obtains NIW Approval with Our Diligent Help
Client’s Testimonial:
“Thanks to you for helping me with filling out the EB2 application. You have been great throughout the process.”
On May 16th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Assistant in the Field of Pharmaceutical Science (Approval Notice).
General Field: Pharmaceutical Science
Position at the Time of Case Filing: Graduate Assistant
Country of Origin: India
State of Residence at the Time of Filing: Iowa
Approval Notice Date: May 16th, 2022
Processing Time: 5 months, 4 days
Case Summary:
“[Client’s] development of novel approaches to characterize and improve the physical properties of solid drug formulations, such as solubility, is integral to the effort to increase the effectiveness of pharmaceutical agents and in turn decrease associated manufacturing costs. By developing widely applicable means to increase the solubility of solid drug formulations, [the client] is directly improving and innovating the field of pharmaceutical science and ensuring that safer and more effective medications are made available to patients within the United States, without the barrier of higher cost.”
The above statement is part of a longer testimonial of support issued in favor of one of our clients from India. She was a graduate assistant in pharmaceutical science and as an expert in the field her proposed endeavors to analyze and characterize cocrystals and amorphous solids in order to enhance aqueous solubility, improve physical drug characteristics, and support pharmaceutical product development. Among other applications, her work was relevant to the improvement of drug properties for cancer, Raynaud’s phenomenon, and other diseases.
Importantly, her work was of great importance because it improved critical properties of pharmaceutical products, supporting public health and the success of the pharmaceutical industry. Her research has contributed innovative strategies for improving solubility and other drug properties, offering improved treatment methods for a variety of diseases. The broad applicability of these advancements and the significance of the global pharmaceutical market is thus strong evidence of the importance of her research.
At the same time she has completed at least 39 reviews to date and her work has been published in 13 peer-reviewed journal articles (4 of them first-authored) and 1 first-authored book chapter.
These publications have also been cited a total of 140 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pharmaceutical science.
Thus, her 8 years of work in the field was indeed helpful in giving her an upper hand in the field. Her expertise is much valued and her work is of great interest to the United States of America. We are glad to have worked with her on the case and help her get the approval without an RFE in just 6 months.